Pediatr. praxi. 2016;17(3):154-156 | DOI: 10.36290/ped.2016.035

The use of Imunoglukan P4H® cream in supportive treatment of atopic eczema

doc.MUDr.Miloš Jeseňák, PhD.1, Mgr.Andrea Vrtíková2
1 Klinika detí a dorastu, Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine
2 Pleuran s. r. o., Bratislava

Atopic eczema (AE) is one of the most frequent chronic skin disorders in childhood. Essential therapy of atopic eczema can be appropriately supported by natural topical immunomodulator containing the complex of biologically active polysaccharides – Imunoglukan®, which efficacy and safety have been confirmed in the recently completed open-label observational study ATREI.

Keywords: atopic eczema, complementary therapy, biologically active polysaccharides, ATREI

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jeseňák M, Vrtíková A. The use of Imunoglukan P4H® cream in supportive treatment of atopic eczema. Pediatr. praxi. 2016;17(3):154-156. doi: 10.36290/ped.2016.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Červenková D. Atopická dermatitída - čo by sme mali vedieť! Dermatol. Prax? 2012; 6: 96-107.
    2. Ondriová I, Cínová J, Mrozková S. Psychosociálna dimenzia kvality života dieťaťa s diagnózou atopický ekzém. Pediatria (Bratisl.) 2012; 7: 121-125.
    3. Jakušová Ľ. Diéta v liečbe atopického ekzému u dojčiat. Pediatria (Bratisl) 2006; 1: 94-96.
    4. Jeseňák M, Havlíčeková Z, Plameňová I, et al. Atopický ekzém a jeho liečby v detskom veku. Pediatria (Bratisl.) 2008; 3: 35-42.
    5. Boneberger S, Rupec RA, Ruzicka T. Complementary therapy for atopic dermatitis and other allergic skin disorders: facts and controversies. Clin Dermatol 2010; 28: 57-61. Go to original source... Go to PubMed...
    6. Soyer OU, Aksoy I, Dallar Y. The use of alternative medicine in children with atopic dermatitis. Allergol Immunopathol (Madr) 2013; 41: 275-276. Go to original source... Go to PubMed...
    7. Jesenak M, Banovcin P, Rennerova Z, Majtan J. ?-glucans in the treatment and prevention of allergic diseases. Allergol Immunopathol (Madr) 2014; 42: 149-156. Go to original source... Go to PubMed...
    8. Majtan J, Kumar P, Koller J, et al. Induction of metalloproteinase 9 secretion from human keratinocytes by pleuran (beta-glucan from Pleurotus ostreatus). Z Naturforsch C 2009; 64: 597-600. Go to original source... Go to PubMed...
    9. Wei D, Williams D, Browder W. Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int Immunopharmacol 2002; 2: 1163-1172. Go to original source... Go to PubMed...
    10. Davis SC, Perez R. Cosmeceuticals and natural products: wound healing. Clin Dermatol 2009; 27: 502-506. Go to original source... Go to PubMed...
    11. Sayama K, Tohyama M, Shirakata Y, et al. Multi-center clinical studies on availability of superfine dispersed ?-glucan (lentinan) on atopic dermatitis. Nishi Nihom Hifuka 2008; 70: 313-318. Go to original source...
    12. Jesenak M, Hrubisko M, Majtan J, et al. Anti-allergic effect of Pleuran (-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections. Phytother Res 2014; 28: 471-474. Go to original source... Go to PubMed...
    13. Jesenak M, Urbancek S, Majtan J, et al. ?-glucan-based cream (containing pleuran isolated from pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis. J Dermatol Treat 2016; 27: 351-354. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.